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ABSTRACT
This study monitored the serotypes of Streptococcus agalactiae (group B streptococcus; GBS) isolated from
invasive infections in western Sweden and investigated possible relationships between serotype, age
and clinical manifestations. Invasive GBS isolates were collected prospectively during 1998–2001 at six
laboratories, covering two counties with a population of 1.8 million, and were serotyped by
coagglutination. Clinical data were obtained from hospital notes. In total, 161 invasive strains (50 from
neonates and infants aged < 3 months, and 111 from adults) were serotyped. The commonest serotypes
from neonates and infants were serotypes III (60%), V (22%) and Ia (10%), and from adults were
serotypes V (42%) and III (25%). Serotype V had doubled in frequency among both children and adults
compared to a previous study from the same area in 1988–1997. Most (80%) of the adults had an
underlying medical condition. No relationship was found between serotype and clinical manifestations.
However, the study demonstrated the importance of active surveillance of GBS serotypes and the
difficulties of formulating a multivalent polysaccharide conjugate vaccine against GBS.
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INTRODUCTION
Streptococcus agalactiae (group B streptococcus;
GBS) is a leading cause of invasive neonatal
infections and infections in pregnant women. In
non-pregnant adults, GBS infection has also
become an increasingly common cause of inva-
sive disease, particularly in elderly persons and
among those with underlying medical conditions
[1–3]. A combination of host and microbial
factors determines the outcome in infected indi-
viduals [4]. Based on the composition of the
capsular polysaccharide, group B streptococci
can be divided currently into nine different
serotypes. The prevalence of different serotypes
varies according to time and geographical loca-
tion [5–12]. Serotypes Ia, Ib, II and III have
predominated in many parts of the world [6,12],
but serotype V has emerged as an increasingly
important pathogen [5,7]. Serum antibodies
against the capsular polysaccharide provide
type-specific protection against invasive GBS
infections [13–16]. The high morbidity and mor-
tality of invasive GBS infections has made the
development of a multivalent conjugate polysac-
charide vaccine a major focus for research
[17–23]. Therefore, knowledge of the distribution
and changes in GBS serotypes in different
populations is important.
The main aim of the present study was to
survey the serotype distribution of invasive GBS
isolates in a Swedish population and to detect
changes in serotype distribution over time. A
second objective was to determine whether the
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serotype distribution differed between age groups
and patients with different clinical manifestations.
MATERIALS AND METHODS
Population-based surveillance
Invasive GBS isolates were collected prospectively from the
six bacteriological laboratories in the counties of Va¨stra
Go¨taland and Halland in western Sweden between 1998 and
2001. These laboratories served all 13 hospitals in the two
counties. The mean population of the surveillance area was
1 767 215, and the total number of live births was 72 641
during the study period (data obtained from the Central
Bureau of Statistics, Stockholm, Sweden; http://www.scb.se).
GBS isolates were collected from normally sterile sites
(blood, cerebrospinal fluid and synovial fluid). Isolates were
identified as GBS by colony morphology, microscopy fol-
lowing Gram’s stain of smears, and coagglutination with
group-specific reagents (Streptex; Murex Biotech, Dartford,
UK). The isolates were stored in broth at ) 70C until
serotyping was performed. Only one isolate from each
infectious episode was included in the study. Clinical data
(age, sex, gestational age, underlying medical conditions,
clinical manifestations and outcome) were obtained from
individual hospital notes. All hospital notes and relevant
data were available for all patients. The policy for intrapar-
tum antimicrobial prophylaxis in the region was the same as
that now recommended by the American College of Obste-
tricians and Gynecologists [24]. The study was approved by
the Ethics Committees of Go¨teborg University and Lund
University.
Serotyping
GBS isolates were serotyped by coagglutination (ESSUM Group
B Streptococcus Serotyping Test; Bacterum AB, Umea˚, Sweden)
with type-specific antisera for serotypes Ia, Ib, II, III, IV, V, VI, VII
and VIII [25]. The only isolate not typeable by coagglutination
was examined with precipitation techniques (ring test and
diffusion test) [26,27] for serotypes I–VIII by J. Motlova´, National
Streptococcus and Enterococcus Reference Laboratory, National
Institute of Public Health, Prague, Czech Republic. Differences
in serotype distribution were compared with chi-squared tests
(2 · 7 tables).
RESULTS
During the period 1998–2001, 165 patients with
167 episodes of invasive GBS disease (annual
incidence of 2.4 cases ⁄ 100 000 inhabitants) were
recorded. In total, 161 invasive GBS isolates were
available for serotyping. Fifty (31%) of these
isolates were obtained from neonates and infants,
and 111 (69%) from adults. No patient with
invasive GBS infection was found in the group
aged 3 months to 18 years. Isolates from six
patients (two neonates and four adults) were lost
from one of the laboratories.
Neonates and infants
During the 4-year period, 52 invasive GBS infec-
tions in neonates and infants aged 0–86 days (33
boys, 19 girls) were documented. Of these cases,
42 (81%) were early onset (< 7 days after birth),
eight were late onset (7–27 days after birth), and
two were very late onset (28 days to 4 months
after birth). The incidence in neonates aged
< 28 days was 0.6 ⁄ 1000 live births, and in neo-
nates and infants aged < 4 months it was 0.7 ⁄ 1000
live births.
Infection without a known focus was the
commonest manifestation (37 cases, 71%). Seven
(13%) patients had meningitis (incidence
0.1 ⁄ 1000), while six patients had pneumonia and
two had septic arthritis. In the early onset group,
32 (76%) of the infections appeared as sepsis
without a focus, six were pneumonia, and four
were meningitis. In the late and very late onset
group, four of the infections were sepsis without a
focus, four were meningitis, and two were arth-
ritis. The serotype distribution compared to clin-
ical manifestations in neonates is shown in Fig. 1.
Eleven (21%) patients were pre-term, i.e.,
< 37 weeks of gestational age. Eight of the pre-
term children had very early onset disease and, of
those, seven had other risk factors for infection
(i.e., mothers with infection or prolonged rupture
of the membrane). Four of the 52 neonates died.
Two died following early onset disease (sepsis
without a focus), and two following late onset
disease (meningitis and sepsis without a focus,
respectively).
Fifty of the GBS isolates from neonates and
infants were available for typing (Table 1). The
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Fig. 1. Serotype distribution among neonates with differ-
ent clinical manisfestations.
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commonest serotypes were serotypes III (60%)
and V (22%). There were no significant
differences related to post-natal age (Table 1),
manifestation (Fig. 1), gestational age, hospital or
outcome (details not shown).
Adults
In adults aged ‡ 18 years, 115 invasive GBS
infections were identified. The incidence was
2.1 ⁄ 100 000 inhabitants ⁄ year. The median age of
the adults (55 males, 60 females) was 68 years
(range 19–96 years). In total, 111 isolates were
available for typing (Table 1). Serotypes III and V
were the commonest serotypes (25% and 42%,
respectively). Serotypes Ia, Ib, II and IV were
isolated at similar frequencies (6–9%). The sero-
type distribution related to clinical manifestations
is shown in Table 2. Ninety-four (82%) patients
had a known underlying medical condition, with
the commonest being diabetes mellitus (n = 30)
and malignant disease (n = 26). Ten (9%) patients
were pregnant. Ten (9%) patients died during or
soon after the infection. The serotypes isolated
from these latter ten patients were Ia (four), Ib
(two), III (two), IV (one) and non-typeable (one).
Two patients had two infectious episodes at
intervals of 7 and 3.5 months. The recurrent
infections were caused by the same serotypes as
the initial infections in both patients (serotypes II
and V, respectively). The manifestations were
erysipelas and septic arthritis, respectively. One
patient had Addison’s disease, while the other
patient had a rheumatic disease and bilateral knee
prostheses.
A significant difference in the serotype distri-
bution between adults and neonates was found
(p < 0.002; Table 1), associated chiefly with the
occurrence of serotypes III and V. Table 3 com-
pares the serotyping results with those obtained
in a previous study in the same region [12].
DISCUSSION
In the present study, the annual incidence of GBS
infection was 2.4 ⁄ 100 000 inhabitants, which was
almost identical to that found in a previous
survey of a part of the same area [28]. The
incidence among neonates and infants was also
similar to that found in other studies of neonatal
infections from the Go¨teborg area in western
Sweden, in which the incidence rates were 0.8 and
1.0 ⁄ 1000 [29,30]. The present data were also
consistent with results from other studies in
Europe and North America [6,10,31–33]. How-
ever, comparison with a previous study in the
same region of strains isolated in 1988–1997 [12]
showed significant changes in the serotype dis-
tribution of GBS among strains from both neo-
nates (p < 0.0001) and adults (p < 0.0001). The
most important change in both groups was a
pronounced increase in infections caused by
serotype V. This increase was not paralleled by
a decrease in a single serotype, but there were
Table 1. Serotype distribution among invasive isolates of
group B streptococci
Serotype
Neonates and infants
AdultsEarly onset
Late and very
late onset
No. (%) No. (%) No. (%)
Ia 5 (13) 0 (0) 10 (9)
Ib 1 (3) 1 (10) 10 (9)
II 1 (3) 0 (0) 7 (6)
III 24 (60) 6 (60) 28 (25)
IV 0 (0) 1 (10) 8 (7)
V 9 (23) 2 (20) 47 (42)
Non-typeable 0 (0) 0 (0) 1 (1)
Total 40 10 111
Table 2. Clinical manifestations and serotype distribution
of invasive group B streptococci in adults
Manifestation
No. of patients
Ia Ib II III IV V NT Total
Sepsis, unknown focus 6 1 4 11 3 17 0 42
Erysipelas 1 2 2 4 1 6 1 17
Endocarditis 1 2 0 3 2 3 0 11
Endometritis 0 3 0 1 1 5 0 10
Meningitis 0 0 0 1 0 1 0 2
Arthritis 0 0 0 2 0 7 0 9
Urosepsis 0 1 0 2 0 3 0 6
Other 2 1 1 4 1 5 0 14
Total 10 10 7 28 8 47 1 111
Table 3. Serotype distribution of invasive group B strep-
tococci isolates in the present study compared with a
previous study in the same region
Serotype
Neonates Adults
Berg et al.
[12]
Present
study
Berg et al.
[12]
Present
study
No. (%) No. (%) No. (%) No. (%)
Ia 14 (18) 5 (10) 4 (6) 10 (9)
Ib 2 (3) 2 (4) 15 (23) 10 (9)
II 4 (5) 1 (2) 10 (15) 7 (6)
III 48 (62) 30 (60) 19 (29) 28 (25)
IV 2 (3) 1 (2) 1 (2) 8 (7)
V 7 (9) 11 (22) 14 (21) 47 (42)
Non-typeable 1 (1) 0 (0) 3 (5) 1 (1)
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smaller decreases in the proportions of several
other serotypes. Serotype V was first reported in
1985 [34], and is now the commonest serotype
among adults in North America, Taiwan and
Zimbabwe [7,8,10,35], as well as in the present
study. Recent studies from Canada and Taiwan
[6,35] also show the importance of GBS type V in
neonates, although serotype III has been, and
remains, the commonest serotype in Europe and
North America [6,10,12,31,33,36]. Type III was
also the second most common serotype in adults
in the present study, and has been the second or
third most common serotype in adults in other
recent studies [5,7,10]. Compared to serotypes III
and V, all other serotypes were uncommon, and
only type Ia has been more important in a few
studies [5,37]. In the present study, serotype Ia
accounted for 10% of the neonatal cases and 9%
of the adult cases.
It is important to note that non-typeable strains,
which are probably non-capsulated, have been
isolated from patients with invasive infections,
even though the capsule is of major importance
for protection of bacteria against phagocytosis. In
previous studies, the proportion of non-typeable
isolates in invasive infections has varied from 1%
to 10% [10,12,31,37].
The most important source of GBS to which the
neonate is exposed is the maternal genital tract.
Approximately 15–25% of pregnant women are
colonised with GBS in the urethra, cervix and ⁄ or
rectum [36,38]. The serotype distribution of colo-
nising strains is similar to the distribution of
invasive strains, but two studies have shown that
the proportion of serotype III strains is higher
among invasive strains than among colonising
strains [12,36]. This indicates that serotype III
strains may be more virulent than strains of other
serotypes, which could be related to a failure to
mount an adequate serum antibody response to
serotype III during colonisation. There are some
unexplained geographical differences between
the serotype distributions of colonising GBS
strains. The most striking is the high prevalence
of serotypes VI and VIII among pregnant Japan-
ese women [11], while these strains seem cur-
rently to be non-existent or rare in Europe and
North America [5,12,36].
The nine capsular polysaccharides found in
GBS are immunologically distinct, and protection
against invasive infection is achieved by serotype-
specific circulating serum antibodies [13–15]. Sec-
ond to exposure to the organism, the most
important protective factor against invasive infec-
tion in the neonate is probably the concentration
of serum IgG antibodies to the colonising strain(s)
in the mother [13–16], particularly as IgG is
transferred from the mother to the foetus towards
the end of the pregnancy. This forms the basis for
efforts to develop GBS vaccines composed of
relevant GBS capsular polysaccharides. Accord-
ing to the present study, an effective conjugate
vaccine with capsular polysaccharide of GBS
serotypes Ia, III and V would, theoretically,
provide protection for 84% of all neonatal and
infant cases with a gestational age of > 34 weeks,
and for 76% of all adult cases, in western Sweden.
An experimental multivalent conjugate vaccine
containing serotypes I–III would, theoretically,
prevent 80% of all neonatal and infant cases with
a gestational age of > 34 weeks, and 57% of all
adult cases, in western Sweden [22].
GBS strains also produce one or more strain-
variable and surface-localised proteins. These
include the ca protein [39,40], the R1–R4 proteins
[41,42], the Rib protein [43] and the Sip protein
[44]. Studies from Canada have demonstrated
that the Sip protein is produced by all GBS
isolates, and that vaccination with recombinant
Sip protein protects adult mice against experi-
mental GBS infection [44,45].
In conclusion, the pronounced changes in the
serotype distribution of GBS strains that have
occurred in western Sweden during a relatively
short period of time demonstrate the difficulty in
formulating a capsule-based GBS vaccine. Alter-
native strategies for prevention of GBS infections
should be considered, e.g., vaccines based on GBS
surface proteins that are common to all or most
GBS strains.
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